Prioritising and optimising multi-medication in multimorbidity

Not Applicable

Completed

• Conditions: Multi-morbidity; Signs and Symptoms

• Registration Number: ISRCTN99526053
• Lead Sponsor: Johann Wolfgang Goethe University (Germany)

Brief Summary

2018 results in: https://www.ncbi.nlm.nih.gov/pubmed/29478012 2018 results in: https://www.ncbi.nlm.nih.gov/pubmed/30055583

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-08-31
• Study Completion: 2012-02-29
• Last Update Posted: 14 October 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 502

Inclusion Criteria

Patients:
1. At least 60 years old of both sexes
2. At least three chronic diseases affecting two or more organ systems, which require pharmaceutical treatment
3. At least five long-term prescriptions with systemic effects
4. Health care provided by GP (at least one contact in most recent quarter)
5. Patient is legally competent to sign any documents
6. Ability to understand and participate in trial of own free will, to fill out questionnaires and participate in telephone interviews
7. Written informed consent to participate in trial

Practices:
1. Practice serves members of the German statutory health insurance system
2. GP practice
3. Physician is specialised in general practice or internal medicine, or doctor with no specialist field
4. Internet access
5. Investigator's agreement to fulfil the contractual obligations arising from the trial
6. Investigator's agreement to the training of a health care assistant (HCA) from the practice for the intervention, as required by the trial

Exclusion Criteria

Patients:
1. Diseases cause life expectancy of less than 12 months
2. Abuse of alcohol or illegal drugs and visible clinical signs or symptoms thereof
3. Cognitive impairment that prevents trial participation (mini-mental state examination [MMSE] less than 26)
4. Emotional stress that prevents trial participation
5. Participation in a clinical trial within the last 30 days

Practices:
1. Practice focuses on unconventional medical treatments
2. Practice focuses on special indications (e.g. human immunodeficiency virus [HIV])

Study & Design

• Study Type: Interventional
• Study Design: Not specified